Annual CFO
-$102.83 M
+$50.26 M+32.83%
31 December 2023
Summary:
Kymera Therapeutics annual cash flow from operations is currently -$102.83 million, with the most recent change of +$50.26 million (+32.83%) on 31 December 2023. During the last 3 years, it has fallen by -$190.96 million (-216.68%). KYMR annual CFO is now -216.68% below its all-time high of $88.13 million, reached on 31 December 2020.KYMR Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$50.19 M
-$7.25 M-16.89%
30 September 2024
Summary:
Kymera Therapeutics quarterly cash flow from operations is currently -$50.19 million, with the most recent change of -$7.25 million (-16.89%) on 30 September 2024. Over the past year, it has dropped by -$18.54 million (-58.59%). KYMR quarterly CFO is now -138.12% below its all-time high of $131.67 million, reached on 30 September 2020.KYMR Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$124.67 M
-$18.54 M-17.47%
30 September 2024
Summary:
Kymera Therapeutics TTM cash flow from operations is currently -$124.67 million, with the most recent change of -$18.54 million (-17.47%) on 30 September 2024. Over the past year, it has increased by +$25.73 million (+17.11%). KYMR TTM CFO is now -215.23% below its all-time high of $108.20 million, reached on 30 September 2020.KYMR TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KYMR Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +32.8% | -58.6% | +17.1% |
| 3 y3 years | -216.7% | -34.7% | -12.7% |
| 5 y5 years | -475.6% | - | - |
KYMR Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -216.7% | +32.8% | -723.9% | at low | -26.6% | +20.5% |
| 5 y | 5 years | -216.7% | +32.8% | -138.1% | at low | -215.2% | +20.5% |
| alltime | all time | -216.7% | +32.8% | -138.1% | at low | -215.2% | +20.5% |
Kymera Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$50.19 M(+16.9%) | -$124.67 M(+17.5%) |
| June 2024 | - | -$42.94 M(+8.4%) | -$106.13 M(+7.8%) |
| Mar 2024 | - | -$39.59 M(-592.1%) | -$98.45 M(-4.3%) |
| Dec 2023 | -$102.83 M(-32.8%) | $8.04 M(-125.4%) | -$102.83 M(-31.6%) |
| Sept 2023 | - | -$31.65 M(-10.2%) | -$150.41 M(-1.7%) |
| June 2023 | - | -$35.26 M(-19.8%) | -$153.03 M(-2.4%) |
| Mar 2023 | - | -$43.97 M(+11.2%) | -$156.76 M(+2.4%) |
| Dec 2022 | -$153.09 M | -$39.54 M(+15.4%) | -$153.09 M(+0.8%) |
| Sept 2022 | - | -$34.27 M(-12.1%) | -$151.90 M(-1.9%) |
| June 2022 | - | -$38.98 M(-3.3%) | -$154.89 M(+5.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$40.30 M(+5.1%) | -$146.42 M(+13.5%) |
| Dec 2021 | -$128.95 M(-246.3%) | -$38.35 M(+2.9%) | -$128.95 M(+16.5%) |
| Sept 2021 | - | -$37.26 M(+22.1%) | -$110.66 M(-289.9%) |
| June 2021 | - | -$30.51 M(+33.7%) | $58.27 M(-24.7%) |
| Mar 2021 | - | -$22.82 M(+13.7%) | $77.36 M(-12.2%) |
| Dec 2020 | $88.13 M(+392.2%) | -$20.07 M(-115.2%) | $88.13 M(-18.5%) |
| Sept 2020 | - | $131.67 M(-1253.8%) | $108.20 M(-561.0%) |
| June 2020 | - | -$11.41 M(-5.3%) | -$23.47 M(+94.7%) |
| Mar 2020 | - | -$12.06 M | -$12.06 M |
| Dec 2019 | $17.91 M(-200.2%) | - | - |
| Dec 2018 | -$17.86 M | - | - |
FAQ
- What is Kymera Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Kymera Therapeutics?
- What is Kymera Therapeutics annual CFO year-on-year change?
- What is Kymera Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Kymera Therapeutics?
- What is Kymera Therapeutics quarterly CFO year-on-year change?
- What is Kymera Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Kymera Therapeutics?
- What is Kymera Therapeutics TTM CFO year-on-year change?
What is Kymera Therapeutics annual cash flow from operations?
The current annual CFO of KYMR is -$102.83 M
What is the all time high annual CFO for Kymera Therapeutics?
Kymera Therapeutics all-time high annual cash flow from operations is $88.13 M
What is Kymera Therapeutics annual CFO year-on-year change?
Over the past year, KYMR annual cash flow from operations has changed by +$50.26 M (+32.83%)
What is Kymera Therapeutics quarterly cash flow from operations?
The current quarterly CFO of KYMR is -$50.19 M
What is the all time high quarterly CFO for Kymera Therapeutics?
Kymera Therapeutics all-time high quarterly cash flow from operations is $131.67 M
What is Kymera Therapeutics quarterly CFO year-on-year change?
Over the past year, KYMR quarterly cash flow from operations has changed by -$18.54 M (-58.59%)
What is Kymera Therapeutics TTM cash flow from operations?
The current TTM CFO of KYMR is -$124.67 M
What is the all time high TTM CFO for Kymera Therapeutics?
Kymera Therapeutics all-time high TTM cash flow from operations is $108.20 M
What is Kymera Therapeutics TTM CFO year-on-year change?
Over the past year, KYMR TTM cash flow from operations has changed by +$25.73 M (+17.11%)